Flavia D’Alessio joined the European Vaccine Initiative as Project Manager in September 2013. She obtained a joint PhD degree in biology in 2012 from the European Molecular Biology Laboratory (EMBL) and the Heidelberg University, where she also continued her work as Postdoctoral Researcher and attended a course in Project Management. Flavia holds a Master of Science degree in Pharmaceutical Biotechnology from the University of Naples “Federico II” and carried out her Master thesis research at the Telethon Institute of Genetics and Medicine (TIGEM) in Naples. Flavia has authored and co-authored scientific articles published in international journals.
Dr. Depraetere obtained a PhD in Biochemistry from the University of Leuven. Following her doctoral studies, she worked as a postdoctoral scientist before transitioning into industry, as senior scientist at the diagnostic company RSR, Cardiff UK. Subsequently, Dr. Depraetere worked as senior scientist preclinical development at Thrombogenics, Belgium. She joined the global regulatory affairs department of GSK Biologicals in 2006 where she led an international team. Dr. Depraetere has extensive experience in vaccine development and regulatory affairs, having worked for more than 15 years in the pharmaceutical industry. In 2016, she joined the European Vaccine Initiative, where she coordinates several projects and is committed to strengthen EVI’s position as a solid and sustainable organization, with the main focus on supporting the development of vaccines for diseases of poverty, neglected and emerging diseases. In March 2019 she took up the position of acting executive director at EVI.
A native German with a good command of English, Sandra Hauenstein joined EVI in September 2014 as Finance Assistant working closely with the Financial Manager. Between 1996 - 1998 she studied international tourism management at a professional school in Thüringen. She has previously worked for NH Hotels in Berlin, as Revenue Manager, and as Reservations Manager at 5* Al Murooj Rotana Hotel in Dubai, returning to Berlin in 2006 as Revenue Manager for Germany's second largest hotel, Park Inn. In 2013 Sandra obtained qualitifcations in Financial Accounting at Computer-controlled Accounting Systems in Mannheim.
Sophie joined EVI in January 2010, and is responsible for overseeing pharmaceutical and subsequent production of vaccine candidates, as well as ad hoc clinical development. In 2014 she was promoted to Vaccine Development Leader.
Until 2001, Sophie worked as a Scientific Researcher in the Molecular Parasitology Laboratory and Applied Genetics Laboratory of l’Université Libre de Bruxelles (ULB), before joining Henogen, Belgium as Chief Scientific Officer and Head of Henogen’s Proprietary Products Platform. During the 2000s, Sophie was in charge of the development of several biotech derived human drugs and vaccines.
Sophie graduated in 1984 with a Master’s degree in Molecular Zoology from ULB, followed by a PhD in Sciences, which she obtained in 2001. She underwent extensive training in the field of Good Manufacturing Practice and Good Clinical Practice. Sophie has submitted several successful patent applications and has authored and co-authored numerous scientific articles in peer reviewed journals.
Stefan joined the European Vaccine Initiative (EVI) in June 2012 as Business Manager to head and manage the business development activities of EVI. In 2014 he was promoted to Head of Business Development. Prior to 2012 Stefan was Managing Director and co-founder of a biotechnology company in Spain which focused on the discovery and development of drugs against rare cancers. Previously, he occupied different management positions related to business development in Spain´s three most renowned biomedical research centres, the Centro Nacional de Investigaciones Oncológicas, Centro de Regulación Genómica, and Centro Nacional de Investigaciones Cardiovasculares. His professional experience also includes a secondment at the Directorate General for Research, Directorate F - Health, at the European Commission in Brussels. Before that he worked for more than ten years as researcher at King´s College London, at the Centre National de la Recherche Scientifique (CNRS), Paris, and at the Max-Planck Institute for Psychiatry in Munich.
Stefan obtained a PhD in sciences from the Ludwig-Maximilians-University in Munich and holds an executive Master of Business Administration (MBA) from the Instituto de Empresa (IE, Madrid).
Thorsten joined EVI in January 2011 as Accounting Assistant to the Financial Director Sten Larsen, and was promoted to Financial Manager in 2013.
Until August 2010 Thorsten was with the international division of the German Railways (Deutsche Bahn).
In 2005, Thorsten took an MSc degree in Economics at Heidelberg University and he is currently studying to become a Certified Accountant at Collegium Academiae, Darmstadt. Thorsten also has a M.A. degree in Sinology from Heidelberg University, and has studied Mandarin Chinese at the University in Shanghai. Apart from his native tongue German, Thorsten is fluent in English and Mandarin Chinese and has a basic knowledge of French and Italian.
Sten officially joined EVI in 2009, and is the Finance & HR Director. He oversees all internal and external financial and economic matters, via various international collaborations. Sten is also responsible for the Human Resources of EVI.
Prior to that, he was seconded to European Malaria Vaccine Initiative (EMVI, now EVI) by the hosting institution Statens Serum Institut (SSI), Copenhagen, where he held the position of Financial Manager.
Before joining SSI in 2007, Sten lived and worked in both Iceland and Denmark employed in various positions from General Management to Sales and Marketing, in both the public and private sector, where he gained broad experience in both segments.
In 2004, Sten obtained a diploma as Marketing Economist from Lyngby Business Academy, Denmark with a dissertation of excellence in Hydrogen Economy, followed in 2005, by a BA (arts of honours) in Economics from Ruskin University. Since then Sten has supplemented his BA with various courses in International Financial Reporting Standards and Business Economics & EC Management.
Nicola joined the European Vaccine Initiative (EVI) in May 2011 as Project Manager. In 2015 she was promoted to Leader Strategic Research, and in June 2018 to Chief Scientific Officer.
Nicola has almost 20 years’ experience in research mainly in the field of infectious diseases, including several years’ experience in vaccine development, research management and pharmaceutical industry (Roche Diagnostics).
In 2003, Nicola graduated with a Dr. rer. nat. in Biosciences from the Ruprecht-Karls-Universität, Heidelberg, followed by post doc studies at Institut Pasteur, Paris. She is skilled in various laboratory techniques and methods, and has attended numerous and varied courses in recent years. In August 2017, she was awarded with the Project Management Professional (PMP®) certification by the Project Management Institute (PMI).
Apart from her native tongue German, Nicola is fluent in English and French.
Nicola has authored/co-authored ~25 articles, mainly on the clinical development of malaria vaccine candidates and host-pathogen interactions, published in peer reviewed international journals.
As Head of Project Leader Unit, Nicolas is in charge of the pharmaceutical development and subsequent production of vaccines - for use in clinical trials - directly funded by the European Vaccine Initiative (EVI), and European projects funded from other sources coordinated by EVI. Nicolas was engaged as a consultant in 2009.
Nicolas’ early career took him to the Al Ain University, United Arab Emirates as a researcher for a short period before becoming a research engineer for Solvay and l’Université Libre de Bruxelles (ULB). His work led to a world patent for the former. 1997/1998 saw him as Management Trainee at SmithKline Beecham Biologicals (now GSK Biologicals) in Belgium where he gained knowledge in cell culture processes, Good Manufacturing Practices and vaccinology. Short periods with other companies in Belgium augmented his experience with urban and industrial wastewater treatment processes, fermentation processes, shift production planning and integrated Supply Chain, after which he worked for Henogen, Belgium from 2000 - 2006, where, as Head of Process Development, Business Development Director and Site Director, he further enhanced his skills and knowledge. In 2006, Nicolas established a management and consulting company Zythum S.P.R.L., offering services to biotech and pharmaceutical companies in process development, cGMP manufacturing, CMOs management, project management, business development and general management.
In 1994 and 1999, Nicolas obtained a Masters in Chemical Engineering, and a Masters in Molecular Biology and Biotechnology respectively from ULB.
Monika Ślęzak joined EVI in March 2018 as a Project Manager. She has 10 years of research experience using molecular and cellular biology approaches in a drug development environment with the focus on preclinical toxicity. She has obtained a PhD in 2009 at the Jagiellonian University in Cracow (Poland), defending the thesis focused on the genotoxic effects of acute CO poisoning in human subjects. Since then, her scientific path has been tightly connected to the Discovery and Preclinical Research, including mice and zebrafish animal models. She has been involved in project management of EU-funded projects since 2008.
She has worked as a project leader at Selvita SA, one of the largest drug discovery companies in Central Europe, headquatered in Krakow (Poland), and at the Molecular Biodicovery Lab at KU Leuven in Belgium. In 2011 she obtained the IPMA Project Manager Associate Certificate. In 2018 she received extensive training in the field of Good Clinical Practice during the CRA training in Pharmaakademie (Mannheim).
Wolfgang Herzog, born 1953 in Neuwied (Rhineland-Palatinate), is the Dean of the Medical Faculty Heidelberg, and since 2004 Head of the Department of General Internal Medicine and Psychosomatics. He began his physics studies in Göttingen and Berlin before turning to medicine, and completing his medical studies in Göttingen. In 1981, Wolfgang came to Heidelberg for the first time as a resident; he then completed his doctoral thesis at the University of Göttingen before returning to Heidelberg for specialist training in the Department of General Internal Medicine and Psychosomatics at the University Hospital Heidelberg - where he has remained since. He is also Speaker of the Senate of the University of Heidelberg, as well as being a member of the Scientific Advisory Board of the German Medical Association and the German Association of Psychotherapists. Key research areas are eating disorders, somatoform disorders, co-morbidity of physical and mental diseases, clinical studies.
Clemens Kocken is Chairman of the Department of Parasitology at the Biomedical Primate Research Centre (BPRC), Rijswijk. After graduation from Groningen Universtity, The Netherlands in 1984 Biochemistry/Molecular Biology), Clemens Kocken obtained a PhD at the same university in 1989 with a thesis entitled “Recombinant Fusion Proteins of Herpes Simplex Virus Type 1 Glycoprotein D- expression in Escherichia coli, purification and immunological properties”.
He then held a postdoctoral position for five years at Nijmegen University, where he worked on malaria transmission-blocking vaccine development. In 1994 he joined BPRC to work in Alan Thomas’ Parasitology Department. Here he worked on the development of AMA1 as a malaria vaccine candidate, on developing non-human primate malaria drug models, and on transfection systems for non-human primate malarias.
The research of the Department of Parasitology is focused on developing vaccines and drugs against malaria and TB, using non-human primate models. Current topics include vaccine efficacy testing and immune correlates of TB, AMA1 as a malaria blood stage vaccine candidate in clinical development and development of new drugs active against malaria hypnozoites.
Claude Leclerc is Professor at the Institut Pasteur and Head of the Immune Regulation and Vaccinology Unit. Claude Leclerc received her Masters degrees in Biochemistry and Immunology in 1973 and 1974, followed by a PhD in Immunology in 1981, all from the University of Paris VII. She has worked in vaccinology for 40 years, and has contributed to the development of synthetic adjuvants and peptidic vaccines and of several innovative delivery systems and cancer vaccines.
Claude undertakes various responsibilities in the administration of research, including being a member of the Institut Pasteur Board of Directors and President of the Scientific Advisory Board of the Cochin-Pasteur Clinical Investigation Center in Vaccinology. She has been the Vice President of the Scientific Council of Institut Pasteur.
Claude has had over 290 papers in renowned scientific journals published, and she holds 25 patents, several of which enabled the creation of Genticel, a biopharmaceutical company that develops therapeutic anti-cancer vaccines. She sits on the Editorial Board of several journals, including Microbes and Infection and the International Journal of Oncology.
For her research in immunology and vaccinology, Claude has received numerous awards and honors, and was nominated Chevalier of the Legion of Honour by the French Republic in 2008.
Samuel McConkey graduated from the University of Dublin, Trinity College in 1989, quickly followed by membership of the Royal College of Physicians of Ireland and diplomas in Child Health and Tropical Medicine and Hygiene, and augmented in 2000 with a Master of Arts in Mathematics and Statistics from Washington University, St. Louis, Missouri and a Doctor of Medicine in 2002 from Trinity College. During the 1990s and early 2000s, Samuel McConkey underwent extensive hands-on postgraduate training, followed by fellowships at a.o. Nuffield Department of Clinical Medicine, Oxford from where he was seconded to the Medical Research Council Laboratories in The Gambia. Samuel McConkey is Associate Professor and has held the position of Head of Department of International Health and Tropical Medicine at the Royal College of Surgeons in Ireland since 2006. He has over 40 publications in peer reviewed publications to his credit.
Samuel McConkey’s areas of expertise can be summarised as follows: HIV, Hepatitis B, HTLV1, Malaria and Tuberculosis, Clinical trials, social sciences.
Professor David Salisbury is the representative of the Jenner Vaccine Foundation on the EVI/EEIG Board. David was previously Director of Immunisation at the Department of Health, UK, where he led a multidisciplinary team and was responsible for implementation of the national immunisation programme, as well as lecturing nationally and internationally on many aspects of immunisation, focusing on the challenges of introducing new vaccines. Professor Salisbury continues to work extensively for the World Health Organization (WHO) on the Global Programme for Vaccines, with the Gates Foundation on malaria and is President of the International Association of Immunization Managers. He is an Associate Fellow at the Centre for Global Health Security, Chatham House, London, and also works as an independent consultant.
Professor Salisbury graduated from London University in 1969, and trained as a paediatrician at the Hospital for Sick Children, Oxford and Great Ormond Street, London.
He is a Fellow of the Royal College of Physicians, Fellow of the Royal College of Paediatrics and Child Health, and a Fellow of the Faculty of Public Health, as well as being an honorary Chair at Imperial College London. He is Chairman of the European Region Certification Commission for Poliomyelitis eradication, and is a member of the Eastern Mediterranean Polio Elimination Certification Commission and the South East Asian Polio Elimination Certification Commission. Between 2005 – 2010 he served as the Chairman of WGO Strategic Advisory Group of Experts (SAGE) on vaccines, and as a member of WHO’s Global Advisory Committee on Vaccine Safety. He is the Co-chairman of the influenza Pandemic Preparedness Group for the Global Health Security Action Group of G7 countries, and is a Liaison Member of the US Advisory Committee on Immunization Practices (ACIP), and the US National Vaccine Advisory Committee, as well as Chairing the European Vaccine Advisory Group for the European Centre for Disease Control (ECDC) and is a member of the Policy and Practice Committee for the GAVI Alliance.
Professor Salisbury has authored around 80 publications on immunisation and paediatric topics , and was made a Companion of the Order of the Bath in the Queen’s 2001 Birthday Honours.
Martin Trillsch has since 2009 been part of the legal council at the University Clinical Centre Heidelberg, and Head of Third Party Funds Management since 2012. Before joining the University of Heidelberg, Martin was employed by an international law firm in medicine law, and the University Clinical Centre in Münster. He studied law in Marburg, Münster and Melbourne, and is a Master of Law.
Marita Troye-Blomberg is Head of the Department of Immunology at the Wenner-Gren Institute (WGI), Stockholm University. The department of Immunology has a long tradition in studies of innate, mucosal, and placental, as well as classical acquired immune responses, in both human and experimental mouse models. A large proportion of its activities is devoted to malaria research with special emphasis on immune-regulation, immune evasion mechanisms, and genetics. The unit started in 1979, and currently involves 25 persons, including scientists, post.docs, post-graduate students, and technical staff. It also accepts long- and short term fellows from developing countries. The unit has extensive collaborations with Mali, Benin, Tanzani, Sudan, Burkina Faso and Cameroon. The unit works in close collaboration with the group of I. Faye in the Department of Genetics, which has been devoted to research on the A. gambie mosquito and P. berghei for the past five years. The unit has state-of-the-art equipment and facilities, including a BSL3 for working with the A.gambie mosquito. The department has access to several core facilities such as cytofluorimetry, QC-PCR machines, confocalmicroscopy, mass spectrometer, mouse breeding facilities etc.
Marita has a long standing experience with international projects and has been involved in several European Commission FP5, FP6 and FP7 funded projects and Networks of Excellence. Marita served as a valued member of the independent EVI Scientific Advisory Committee for six years.
Charles de Taisne
Charles de Taisne is currently Senior Director Corporate Development at Sanofi Pasteur. He holds a PhD in microbiology (Institut Curie, Paris) and a MBA. He conducted his post-doctoral research at the Institut Pasteur of Lille in Dr Stehelin laboratory. After joining Sanofi Pasteur, he was responsible for various vaccine research projects on viral vaccines and malaria (P falciparum) vaccines. Most of these projects involved collaboration with academic and private institutions. Charles held various positions in Sanofi Pasteur R&D before transitionning to Corporate Development. He has been a member of various boards – among them the EMVI board- and experts committees.
Dr.Suresh Jadhav, M.Pharm. Ph.D. is currently Executive Director of Serum Institute of India Ltd., one of the largest vaccine manufacturers from the developing countries, supplying vaccines at affordable prices. Dr. Jadhav is associated with Developing Countries Vaccine Manufacturers’ Network (DCVMN) since its inception in 2000 and was the President of DCVMN from 2003 till 2008. He is currently a member of GAVIBoard, EVI Board of STakeholders, FastVac, besides a member of the Program & Policy Committee of GAVI. He is also associated with various advisory committees/Task Force of Sabin Vaccine Institute, WHO IVR and Decades of Vaccines – Protection & Synergies Group etc. Dr.Jadhav is also affiliated with several Indian universities, AICTE, UGC, State Directorate of Technical Education etc. He has participated in several collaborative studies for making revisions in international reference standards for WHO, NIBSC, NVI etc. and has published more than 60 technical papers in the national & international journals.
Diarmuid O’Donovan is the representative of Irish Aid on the EVI Board of Stakeholders where he is Vice Chair. Diarmuid O’Donovan is Director of Public Health with the Irish Health Service Executive (West) and Senior Lecturer in Social and Preventive Medicine at the National University of Ireland Galway where he coordinates teaching on public health and on global health and development. He is involved in research in Ireland and several African countries. Research interests include equity, information systems, reproductive and child health, communicable disease control, STIs, HIV, and environmental health and sustainable development.
Jean-Paul H. Prieels
In February 2011 Jean-Paul Prieels became a consultant, after several years as Senior Vice President, Research and Development at GlaxoSmithKline. In 1975 Jean-Paul obtained a Ph.D. in Biochemistry at the Free University of Brussels (ULB), Belgium, and in the following years became Associate Professor at the same institution. He holds several key non-executive positions in prestigious European companies. Jean-Paul has authored, co-authored numerous articles published in peer reviewed publications.
Sodiomon Sirima is Head of Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou. He graduated in 1993 with a Doctorate in Medicine and Surgery (MD) from the University of Ouagadougou, followed by a Master of Socio-anthropology (BA) in 1997. His PhD in epidemiology was obtained at “La Sapienza” in 2002.
Between 1993 – 1995 Sodiomon Sirima worked as MD at a medical centre in Burkina Faso. He has also been Principal Investigator on more than twenty epidemiological and community based studies, more than ten drug and malaria vaccines clinical trials.
From 1997 Sodiomon Sirima has been/is a member of several national and international scientific committees and boards in Africa Europe or international Organization.
Sodiomon Sirima has had over 50 articles published in peer reviewed international journals since 1993.
Professor Marcel Tanner is former director of the Swiss Tropical and Public Health Institute (Swiss TPH) in Switzerland and professor of epidemiology and medical parasitology at the University of Basel. He devoted his entire life to develop new drugs and vaccines for the eradication of malaria and other poverty-related diseases and to find new solutions to strengthen health systems in Africa and the Pacific region. Tanner is chair of the Strategic Advisory Group (SAG) and member of the Malaria Policy Advisory Committee (MPAC) of WHO; chair of the INCLEN Trust, the INDEPTH network and of the Drugs for Neglected Diseases initiative (DNDi). He chairs the Scientific Advisory Board of FIND and is member of the Scientific Advisory Board of the Novartis Institute for Tropical Diseases in Singapore. Marcel Tanner was key in building up research and implementation institutions in Africa, namely the Ifakara Health Institute (IHI) in Tanzania and the Centre Suisse de Recherche Scientifiques (CSRS) in Côte d’Ivoire. In 2016 he was elected President of the Swiss Academy of Sciences (SCNAT) as well as High Level Representative North of European and Developing Countries' Clinical Trials Partnership.
Nancy Le Cam Bouveret
Since January 2012 Nancy Le Cam Bouveret has been an Independent Clinical Development and Regulatory Consultant, with most of her contracts being in the area of vaccines. In the preceding years Nancy held leading positions in the private sector in Canada, a.o. at GSK Biologicals, prior to which she worked in France in both the private and public sector. Between 2002 – 2004 Nancy was Senior Technical Officer, Responsible for Pharmaceutical, Clinical, Regulatory and Business Development at the Program for Appropriate Technology in Health (PATH Europe), as "Focal Point" for the Meningitis Vaccine Project. She sits on the Gates Foundation’s reviewer expert panel for HIV, Tuberculosis, Malaria, Dengue, Rabies.
Nancy was primarily educated at the University of Paris, where she obtained a Doctorate of Medicine in 1983, after which she specialised in health economy, health systems, statistics and epidemiology, and gained a degree in geriatrics in 1984, followed by a certificate in Pharmacokinetics from Droit et Pharmacie, Paris in 1985.
Nancy has authored and co-authored numerous articles published in peer reviewed international publications.
Nancy’s areas of expertise are vaccinology, clinical development, regulatory affairs.
Giuseppe Del Giudice
Since 2006 Giuseppe Del Giudice has been Global Head of Translational Medicine at Novartis Vaccines and Diagnostics, Siena.
After graduating as a Medical Doctor from the University of Milan in 1980, Giuseppe specialised in infectious diseases, and after obtaining his PhD at the University of Geneva in 1989 he worked extensively for the World Health Organization and the universities of Geneva and Lausanne in various capacities, before joining industry in 1996.
Giuseppe is a member of Italian, Swiss and American societies for immunology and parasitology, and has authored/co-authored an impressive number of articles (over 240) in international journals.
Giuseppe’s areas of expertise are immunology, infectious diseases, vaccines, vaccine adjuvants
Dr Joachim Hombach is Senior Adviser in the Department of Immunisation, Vaccines and Biologicals. In his former managerial positions at WHO, he was interim Head of the Initiative for Vaccine Research, and Coordinator in charge of policy & strategy and implementation research. He also served as focal point for the flavivirus vaccine portfolio, with particular emphasis on dengue and Japanese encephalitis vaccines.
Before joining WHO, Joachim Hombach’s career focused on vaccine research and implementation policy, with emphasis on vaccines for the developing world. In this context, he had assignments as Director of vaccine policy at GlaxoSmithKline Biologicals S.A., and as Scientific Officer with the European Commission. In the latter function, he was seminal in setting up the European and Developing Countries Clinical Trials Partnership.
Joachim Hombach’s career started as a researcher in molecular and cellular immunology at the University of Zürich, Switzerland and the Max-Planck Institute for Immunology in Freiburg, Germany. He holds a PhD from the University of Cologne, Germany, as well as a Master of Public Health from Johns Hopkins University, Baltimore, USA. Multiple peer-reviewed publications have emerged from his work.
Joachim Hombach’s areas of expertise can be summarised as follows: Immunology, vaccine development and evaluation; vaccination and public health.
Ingileif Jónsdóttir graduated as a B.Sc in Biology from the University of Iceland in 1975, studied immunology at St.Mary’s Hospital Medical School in London in 1975 and University of Stockholm 1976-1984 where she obtained a Ph.D in 1991. Ingileif has an impressive career with several honors and awards for academic achievement. She was appointed Senior Scientist in 1984, Associate Professor in 1994, and Professor of immunology in 2006 at the Faculty of Medicine at the University of Iceland. Concurrently she is Head of Vaccine Research Unit, Department of Immunology at the University Hospital and Head of Division of Infectious and Inflammatory Diseases, deCODE genetics, Reykjavik. She has vast teaching experience, primarily in the field of immunology, and she supervises several Ph.D and M.Sc students at the University of Iceland. Ingileif’s current research projects are mainly focused on neonatal immunology, vaccination strategies and genetics of infectious diseases and vaccine responses, and she has been Principal Investigator on numerous clinical trials. She also has an impressive record of serving on various Boards, Committees and Working Groups dealing with scientific and ethical issues in both national and international context, as well as having authored several papers/reports in a Nordic context. Ingileif has had over 60 articles published in peer reviewed scientific journals, and is author/co-author of five books.
Ingileif’s areas of expertise can be summarised as follows: immunology, vacciniology, genetics of infectious diseases and vaccine responses, ethics.
Since 1999, as full professor, Michael Lanzer has been Chair of Parasitology at Heidelberg University where, 11 years earlier, he obtained his Ph.D. After several years as postdoc at Sloan-Kettering Institute, New York, Michael held a junior group leader position at the University of Würzburg before being appointed professor at Heidelberg University, since when he has served as coordinator, and has served on several committees in his field of expertise, and is currently Director of the international EVIMalaR PhD Programme, Coordinator of The Hartmut Hoffmann-Berling International Graduate School of Molecular and Cellular Biology and Coordinator of the MD/PhD Programme of his university. In 2011 he was honoured with the Heidelberg Molecular Life Sciences Investigator Award.
Michael has authored and co-authored numerous articles published in top international scientific journals.
Michael’s areas of expertise are Molecular Parasitology, drug resistance mechanisms of the malarial parasite; antigenic variation, cytoadherence, protein trafficking in P. falciparum and membrane transport processes.
Dominique Mazier, is Professor of Parasitology/Mycology at University Pierre et Marie Curie (UPMC) School of Medicine and Head of the Parasitology/Mycology Department at Pitié-Salpêtrière University Hospital. Working as a medical doctor in Africa and South West France in the mid-seventies, she then moved into the field of parasitology and mycology. In more recent years 1997 – 2014 Dominique was Director of several research units at Institut national de la santé et de la recherche médicale (Inserm), latest unit 945, where translational research projects were developed covering a wide range of approaches, from basic research to clinical research on Plasmodium and HIV. She has been instrumental in establishing in vitroand in vivo models of malaria pre-erythrocytic stages sanctioned for the analysis of host immune responses and identification of host molecules that are crucial for hepatic development of the Plasmodium parasite including CD81 and SRB1. These platforms also allow for high-throughput screening efforts to identify novel drugs against Plasmodium liver stages. More recently her group has developed a novel in vitro model of infection with the simian malaria parasite Plasmodium cynomolgi for the study of hypnozoites. This model is currently being exploited to characterise the mechanisms of dormancy and reactivation, and for the screening of drugs active on hypnozoites.
Dominique lends her expertise to several international scientific and grant review/funding committees, including three European Commission, Framework Programme 7 projects. She also supervises students working on Postdoc studies and PhDs, as well as having a handful of patents. Dominique has also authored/co-authored more than 220 articles published in international peer reviewed journals.
Doninique’s areas of expertise are immunology, malaria, molecular biology, drugs
James S. Robertson
Until his retirement in 2013 Dr. Robertson was Principal Scientist, Division of Virology, National Institute for Biological Standards and Control (NIBSC) http://www.nibsc.org/ where he directed an internationally recognised state-of-the-art programme of research and development concerning influenza vaccines, impacting on influenza vaccine manufacture, influenza vaccine control and the WHO Global Influenza Surveillance Network. He advised the European Medicines Agency (EMA) on the regulation of biological medicinal products, EU guidelines and EU regulatory practices, as well as national and international government agencies and pharmaceutical industries on quality issues regarding biological medicinal products. He was responsible for or contributed to a number of vaccine-related EU guidelines and remains a consultant to WHO on influenza vaccine technology transfer to developing countries.
He graduated from the University of Glasgow in 1971 with a B.Sc. (Hons) in Biochemistry, followed by a PhD in 1974, and spent the following years until 1982 in PostDoc. positions in USA and the University of Cambridge, UK.
Dr Robertson is a member/Board member of several international groups related to his areas of expertise, has spoken at numerous international conferences, and has authored more than 140 original scientific papers, articles and reviews.
His areas of expertise are vaccines, regulatory and biological standards.
Mahamadou Aly Thera
Mahamadou Thera graduated in 1986 as a Medical Doctor (MD) from the Institute of Medicine and Pharmacy, Jassy, Romania. In the decade that followed, Mahamadou held several positions in his country of birth, Mali. He served as a military doctor, was chief of the pediatric ward in the Regional Hospital of Gao, was physician in the orthopedics and trauma surgery service, National Hospital Gabriel Touré, fellow in the Department of Public Health, at the Faculty of Medicine, Pharmacy and Dentistry in Bamako, and was coordinator of the Regional Malaria Control Programme for the region of Mopti. In 1996 and 1998 respectively, Mahamadou obtained a Master of Public Health degree and a degree in malariology from the Faculty of Medicine, Pharmacy and Dentistry, in Bamako. In the years that followed he obtained degrees (MSc) in Medical Parasitology, Biostatistics and Conduct of Clinical Trials, and Medical Entomology & Parasitology from Universities in Senegal, France and Mali. Mahamadou has gained wide experience in positions such as Assistant Professor of Parasitology, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, Bamako, and Associate Professor of Parasitology-Mycology at the same university, where he currently holds two positions: Professor of Parasitology-Mycology, and he is Head of the Mali Malaria Vaccine Development Unit, Malaria Research and Training Center.
Throughout Mahamadou’s academic career, he has served as investigator, monitor or DSMB member in numerous drugs and malaria vaccine trials, primarily in Mali, and he has over 40 articles published in peer reviewed journals.
Mahamadou’s areas of expertise can be summarised as follows: malaria epidemiology, clinical trials, ethics, parasitic diseases.
Aissatou Toure graduated from the University of Dakar in 1985 with a degree in pharmacy, and added a degree (M.Sc) in Immunology from the University of Lille to her achievements two years later. This was followed by diplomas from Institut Pasteur, Paris in general and advanced immunology in 1987, and clinical trials and infectious diseases in 2003. Between 1988 – 2006, Aissatou served as Research Assistant with increasing levels of competency at Institut Pasteur, Dakar, and since 1998, has served as Head of Laboratory of Parasite Immunology where she is a senior researcher. Aissatou has and continues to serve on several international committees such as UNESCO and EDCTP, covering areas including Malaria, ethics, quality assurance, health education for women, health research and development, and meningitis. Aissatou has had over 15 articles published in scientific journals.
Aissatou’s areas of expertise can be summarised as follows: Malaria, Epidemiology, Immunology, and Ethics,
Terry became CEO of Valitacell in April 2015, an Irish biotechnology company. Having trained and worked originally as a medical doctor in Dublin, he went on to work in the pharmaceutical industry in Paris and Copenhagen, where he held country Managing Director positions. He was a Principle and lead in the healthcare consulting practice (London office) of the Boston Consulting Group for 6 years. From 2002 to 2013 Terry worked in the Royal College of Surgeons in Ireland where he was Deputy CEO.
Terry is on the Boards of the National Treatment Purchase Fund and the Institute of Banking. He is a member of the Audit Committee and Registration and Continuing Practice Committee of the Medical Council. He is formerly a Director of the Coprorate Governance Association of Ireland and Deputy Chairman of the Dublin Dental Hospital.
Terry holds an MBA (INSEAD), MSc Healthcare Ethics and Law (RCSI), DipCorpGov (UCD), Dip Company Direction (IOD), DCH (UCD) and MB, BCh, BAO, BA (TCD).
Siaka Débé, a native of Burkina Faso, has been granted a Clinical Research and Development Fellowship from the European and Developing Countries’ Clinical Trials Partnership (EDCTP)/Tropical Diseases Research, World Health Organization (TDR/WHO), which commenced at EVI on 15 November 2016.
Siaka graduated in July 2010 with a Doctorate in Medicine (MD) from the University of Ouagadougou. He joined the Centre National de Recherche et de Formation sur le Paludisme (CNRFP) in December 2010 where he was the leader of clinical research units in Banfora and later in Sapone. He is trained in Good Clinical Practice, introduction of clinical research, research protocol development and scientific articles writing.
Throughout his career, Siaka has been responsible for the implementation of several clinical trials and epidemiological studies. He has co-authored several articles that were published in peer reviewed international journals. Siaka plans to pursue a master position in Epidemiology-statistics, Vaccinology and Immunology.
María del Mar Castro
María del Mar Castro, a fellow at EVI, has been granted a Clinical Research and Development Fellowship from the European and Developing Countries’ Clinical Trials Partnership (EDCTP)/ Tropical Diseases Research-World Health Organization (TDR/WHO). Her fellowship commenced on 09 January 2017.
A native of Colombia, María graduated as a medical doctor from Universidad del Magdalena (Santa Marta, Colombia) in 2010. In 2015 she obtained a Msc in Epidemiology from Universidad del Valle (Cali, Colombia). Trained in both good health research practice (GHRP) and good clinical practice (GCP), she also has extensive hands on experience working in a clinical setting. Since 2011, she has participated in several research studies concerning Leishmaniasis serving in various capacities such as physician, clinical coordinator and project manager. María has authored/co-authored several articles published in peer reviewed international journals.
Claus R. Bartram graduated from the University of Hamburg in 1978 with a ´summa cum laude´ Degree in Medicine. He then went on to specialise in paediatrics and gained a DFG scholarship from Erasmus University Rotterdam, Department of Cell Biology and Genetics. In 1987, Claus was appointed Associate Professor and Head of the Section Molecular Biology in the Department of Pediatrics II at Ulm University. This was followed by an appointment to the Chair of Clinical Molecular Biology at the University of Ulm in 1993. In 1995, after obtaining his Board Certification in Human Genetics, he was appointed to the position of Chair of Human Genetics at the University of Heidelberg. Claus is currently Director of the Institute of Human Genetics at the University of Heidelberg and Dean of the Medical Faculty of Heidelberg. He is an active member of a large number of scientific committees and learned societies, e.g. DFG, Leopoldina as well as the German Medical Association, to name but a few. Several prestigious awards have been bestowed on Claus, and he has authored more than 400 articles in peer reviewed scientific journals, books and book chapters.
Claus’s areas of expertise can be summarised as follows: Cancer genetics, Human genetics.
Ruairí Brugha is a medical doctor, public health specialist, Professor and Head of the Department of Epidemiology and Public Health Medicine and Head of the Division of Population Health Sciences at the Royal College of Surgeons in Ireland (RCSI). He has 30 years’ experience in international health, including six years in Africa in the 1980s and 1990s as a clinician, public health specialist and researcher at the district level, primarily researching vaccine delivery systems. He spent 10 years at the London School of Hygiene and Tropical Medicine, where he was Head of the Health Policy Unit 2003-05 and editor of Health Policy and Planning. His research interest is primarily in health systems and policy research, especially in Africa. During the 2000s, he conducted country level studies and published extensively on the effects of Global Health Initiatives, including GAVI and the Global Fund, on country health systems. Much of his current research – in Africa and Ireland – is on understanding and finding solutions to global health workforce constraints and needs.
Claire Boog is Scientific Director of the Netherlands Vaccine Institute (NVI), Bilthoven. She trained as a Medical Biologist (University of Amsterdam, 1983; cum laude), followed in 1988 by a Ph.D at the faculty of Medicine Leiden University while working at the Central Lab. of Blood Transfusion Service (CLB) and the Netherlands Cancer Institute in Amsterdam. Claire then joined the Department of Immunology of the Faculty of Veterinary Medicine, of the University of Utrecht, and was concurrently yearly visiting lecturer at the University of Harare, Zimbabwe teaching immunology up to 1991. 1994 saw her as Head of the Department of Transplantation Immunology at the CLB, in Amsterdam, and in 1999 she became Head of the department of the Immunology of the Laboratory of Vaccine Research of the National Institute of Public Health and Environmental Protection (RIVM), in Bilthoven, where her research activities focused on defining immunological correlates of protection on the T and B cell level after natural infection and vaccination. In 2003 Claire became Head of the Department of Vaccine Research of NVI, where she coordinated and managed the Strategic Vaccine Research Program, designed to form a bridge between fundamental scientists in the field of microbiology, immunology, and vaccinology from (inter)national universities, biotech companies and/or vaccine institutes and NVI. In 2007 she became Deputy Scientific Director of the NVI, and also Professor at the Department of Infectious Diseases and Immunology at the Faculty of Veterinary Medicine, University of Utrecht.
Claire has authored or co-author ~100 publications and is (or was) a member of several national scientific boards.
Alister Craig graduated in 1981 from the University of Edinburgh with a B.Sc. in Genetics. This was followed by Ph.D. studies at the University of Leicester, completed in 1984 with a thesis entitled “The Gene Family Encoding a Major Glycoprotein in the Murine Submaxillary Glands”. Several post doctoral research fellowships followed at prestigious institutions abroad and at home in England. Alister Craig has been associated with the Liverpool School of Tropical Medicine (LSTM) since 1999, where he currently holds the position of Professor of Molecular Parasitology and is Dean of Biological Sciences.
In his own words Alister Craig’s main interests in research 'are the mechanisms of cytoadherence in Plasmodium falciparum and its role in severe disease'. Alister Craig has authored and co-authored numerous articles published in top international scientific journals.
Alister Craig’s areas of expertise can be summarised as follows: Malaria, Cell Biology, Molecular Biology, disease mechanisms.
Juhani Eskola graduated as a Doctor of Medical Science from the University of Helsinki (UH) in 1983, and went on to specialise as a General Practioner (GP) and paediatrician the same year. In 1989, Juhani Eskola was appointed Docent (Associate Professor) in Infectious Diseases at UH. Early on in his career, Juhani Eskola gained hands-on medical experience as a GP and paediatrician, and between 1991 – 1999, held several top positions at the National Public Health Institute (KTL). During the latter part of this period, Juhani Eskola was also Visiting Professor at the Imperial College of Science, Technology and Medicine in London, augmenting his international experience between 2000 – 2003 at Aventis Pasteur, but returning to KTL in 2004. Juhani Eskola currently holds the position of Deputy Director General; Professor at the National Institute for Health and Welfare. Apart from the over 100 articles in international scientific journals, Juhani Eskola has also written seven books.
Juhani Eskola’s areas of expertise can be summarised as follows: Public health, Vaccinology, Immunology, pharmaceutical industry, Preclinical toxicology studies, Clinical trials.
Marja Esveld currently holds the position of Senior Policy Advisor, Department for Social Development, Ministry of Foreign Affiairs, Netherlands.
Marja has been seconded for four years by the Ministry of Health, Welfare and Sports, to support the health team of the MoFA. Her main areas of work are global TB and malaria control, and biomedical research for poverty related diseases. She is health advisor to the Embassy in Vietnam.
As part of her work, she manages grants with Product Development Partnerships (PDPs) in the areas of Aids, TB and other neglected diseases. She is Vicechair of the European Developing Countries Clinical Trials’ Partnership (EDCTP), and represents NL and Sweden on the Board of the UN Special Programme for Tropical Diseases Research (TDR). She also represents the Netherlands and UK on the StopTB Partnership Board.
For the past two years, Marja has been involved in the organisation of meeting on ‘Strengthening pharmaceutical innovation in Africa’, led by COHRED and NEPAD, under the auspices of the African Union. She is also liaison officer for COHRED’s work on strengthening health research capacity in Africa.
Recently, she became involved in inter-ministerial working groups on Life Science, policy coherence and Global Public Goods.
Marja is an infectious diseases epidemiologist by training. She has worked with the National Institute of Public Health (RIVM), the Ministry of Health, the World Health Organization (Geneva) and the Inspectorate for Health Care, before she joined the MoFA.
David Goldblatt is Professor of Vaccinology and Immunology at Institute of Child Health, University College London (UCL) where he heads the Immunobiology Unit and is Director of the WHO Reference Laboratory for Pneumococcal Serology. In addition he is clinically active and is an Honorary Consultant in Paediatric Immunology at Great Ormond Street Hospital for Children, National Health Service Foundation Trust (GOSH, Appointed 1995). In addition he is Director, Clinical Research and Development at GOSH and also Director of theGOSH-UCL National Institute for Health Research Biomedical Research Centre.
David obtained a PhD from University of London (1991), followed in 1994 by a Joint Committee for Higher Medical Training Accreditation in Paediatrics with a special interest in Infectious Diseases.
He emigrated from South Africa to UK in 1985 where he held paediatric positions in London hospitals before embarking on an impressive career at London leading hospital for sick children, Great Ormond Street. Between 1995 – 2000 he was also a Senior Lecturer at UCL
David is or has been a member of numerous prominent societies, associations and committees in Britain and Europe, several of which he has chaired. He is a peer reviewer for several prestigious journals, and has received numerous grants, prizes and awards. He is frequently invited to speak and give lectures all over the world. He has authored and co-authored books and over 100 articles in peer reviewed journal, and has several other publication to his credit.
David’s areas of expertise are paediatrics, immunology and infectious diseases, specifically the immune response to vaccines and infectious diseases with a focus on the meningococcus and pneumococcus and conjugate vaccines.
Brian Greenwood is Manson Professor of Clinical Tropical Medicine at the London School of Hygiene and Tropical Medicine (LSHTM,) which he joined in 1996. He also chairs the Jenner Vaccine Foundation. He qualified in medicine at the University of Cambridge, UK in 1962. Following house-officer appointments in London, he spent 3 years in Western Nigeria as a medical registrar and research fellow at University College Hospital, Ibadan. After receiving training in clinical immunology in the UK, he returned to Nigeria in 1970, this time to help in establishing a new medical school at Ahmadu Bello University, Zaria where he developed his research interests in malaria and meningococcal disease whilst continuing to teach and practice both adult and paediatric medicine.
In 1980, Brian moved to the UK Medical Research Council Laboratories in The Gambia which he directed for the next 15 years. In The Gambia, he helped to establish a multi-disciplinary research programme which focused on some of the most important infectious diseases prevalent in The Gambia and neighbouring countries such as malaria, pneumonia, measles, meningitis, hepatitis and HIV2. Work undertaken during this period included demonstration of the efficacy of insecticide treated bed-nets in preventing death from malaria in African children and demonstration of the impact of Haemophilus influenzae type b and pneumococcal conjugate vaccines when deployed in sub-Saharan Africa.
From 2001 -2008 he directed the Gates Malaria Partnership, which supported a programme of research and capacity development in many countries in Africa, directed at improving treatment and prevention of malaria. In 2008, he became director of a new malaria research capacity development initiative, supported by the Wellcome Trust and the Bill and Melinda Gates Foundation, the Malaria Capacity Development Consortium, which supports a post-graduate malaria training programme in five universities in sub-Saharan Africa. He is also director of a new consortium (MenAfriCar), which is studying the epidemiology of meningococcal infection in Africa prior to the introduction of a new conjugate vaccine.
Brian Greenwood has published over 600 papers on a variety of infectious diseases but particularly malaria. He has acted as an advisor to WHO, the Bill and Melinda Gates Foundation, a number of public private partnerships and pharmaceutical companies engaged in the development of drugs or vaccines for use in the developing world.
Dr Marie-Paule Kieny was appointed WHO Assistant Director-General for Innovation, Information, Evidence and Research in October 2010, for which reason she resigned from EVI SAC. Dr. Marie-Paule Kieny was Director of the WHO Initiative for Vaccine Research (IVR) from 2001 - 2010. Dr Marie-Paule Kieny has had a distinguished career in vaccine research and development. She was assistant scientific director of Transgene S.A., France, where she managed several human or veterinary vaccine projects, and notably the development of a recombinant rabies vaccine this is widely used for the eradication of this disease in wild animals.
She has published over 250 articles and reviews, mainly in the areas of Infectious diseases, Immunology and Vaccinology.
Shabir Madhi is Executive Director of the National Institute for Communicable Diseases, National Health Laboratory Service, Professor of Vaccinology; School of Pathology; University of Witwatersrand, and Co-director, University of Witwatersrand/MRC Respiratory and Meningeal Pathogens Research Unit.
After obtaining a PhD (Health Sciences) from the University of the Witwatersrand in 2003, Shabir embarked on a career at the university, specialising in infectious diseases. He is a member and or chairs several important national and international bodies, associations, societies and organisations, and is currently President of the World Society for Infectious Diseases and World Society of Paediatric Infectious Diseases. Shabir has also undertaken international consultancy and advisory work on numerous occasions, and has received several awards and grants, as well as performing as Principal Investigator on several studies.
Shabir is regularly invited to speak at international conferences, and has contributed to several books and authored/co-authored over 130 articles in peer reviewed journals.
Shabir’s areas of expertise are Pneumo and HIV.
Charles Stephen Mgone
Charles Mgone is the Executive Director of the European & Developing Countries Clinical Trials Partnership (EDCTP). Prof. Mgone is a paediatrician by training and holds a PhD in Medical and Molecular Genetics. He has worked in Africa, Europe and the Pacific where he has served as advisor at international and national levels. He has considerable experience in research, health research ethics, research administration, capacity development and training, particularly in sexually transmitted infections, HIV/AIDS, malaria and other tropical diseases. Before joining EDCTP, Prof. Mgone was the Network Director of the African Malaria Network Trust (AMANET) responsible for coordinating capacity development and networking in accelerating the development and assessment of malaria vaccines and other interventions. Prior to that he was a Research Fellow at the Duncan Guthrie Institute of Medical Genetics, University of Glasgow, the Deputy Director of the Papua New Guinea Institute of Medical Research and adjunct professor of Health Research of University of Papua New Guinea, and professor of Paediatrics and Child Health at the University of Dar es Salaam, Tanzania.
Leo van der Pol
Dr. Leo van der Pol is principal scientist at Intravacc, the Institute for Translational Vaccinology, responsible for the development of processes for both bacterial and viral vaccines. From 2005 to 2013 he was Head of Process Develoment at the Netherlands Vaccine Institute (NVI) and National Institute for Public Health and the Environment (RIVM)-Vaccinology. Before this he was senior scientist and manager Research & Development at the pioneer Contract Manufacturing Company Bio-Intermediair that later evolved to DSM Biologics, involved in process development, scale-up, process validation, and trouble shooting. Though monoclonal antibodies were a model product in his 18 years CMO experience, process development was also performed for enzymes, hormones, blood factors, immuno-modulants and vaccines with different expression systems such as hybridoma, myeloma, CHO, BHK, insect-cell/ baculovirus, adherent animal and human cells.
Leo van der Pol holds a PhD in Bioprocess technology from the Wageningen University & Reseach Centre (WUR). Recent research focuses on vaccine development in accordance with current ICH guidelines (QbD and PAT) and the development of new platform-technology for vaccines.
Eric Nébié, a native of Burkina Faso, has been granted a Clinical Research and Development Fellowship from the European and Developing Countries’ Clinical Trials Partnership (EDCTP)/Tropical Diseases Research, World Health Organization (TDR/WHO), which will commence at EVI on 30 November 2015.
Eric has a Medical Doctorate (MD) from the University of Ouagadougou in 2010, followed by a diploma in vaccinology and courses/training in Good Clinical Practice, monitoring and evaluation, evaluation of malaria programmes and assessment and analysis of malaria indicators of the demographic and health surveys. Following his MD, Eric has held various positions at hospitals/health centres in Burkina Faso, and most recently supervised immunisation campaigns (Polio campaigns, measles and rubella campaign) on behalf of World Health Organization. Eric has participated in several health related projects, and has co-authored articles published in peer reviewed international journals.
Fabrice Somé, a native of Burkina Faso, like EVI’s other fellowship receiver, has been granted a Clinical Research and Development Fellowship from the European and Developing Countries’ Clinical Trials Partnership (EDCTP)/ Tropical Diseases Research-World Health Organization (TDR/WHO), which commenced at EVI on 8 January 2016.
Fabrice obtained one Msc in Animal Biology at the faculty of Sciences Semlalia of the University of Marrakech in 2006, another Msc in Applied Biology at the University of Ouagadougou in 2009, and a PhD in Applied Biology in 2014 at the Polytechnic University of Bobo-Dioulasso.
Since 2007 he worked at the Institut de Recherche en Sciences de la Santé, Direction Régionale de l’Ouest as a research assistant and then associate. In recent years Fabrice has been involved in several projects concerning malaria, as coordinator of projects and laboratory activities, as well as in an administrative capacity. He has authored/co-authored articles published in peer reviewed international journals.
Fassia has been granted a Clinical Research and Development Fellowship from the European and Developing Countries’ Clinical Trials Partnership (EDCTP)/ Tropical Diseases Research-World Health Organization (TDR/WHO). Her fellowship has commenced at European Vaccine Initiative (EVI) on 8 January 2018.
Native of Benin, she obtained a DIT (Diplôme d’Ingénieur des Travaux) in Radiology at “École Polytechnique d'Abomey-Calavi” of National University of Benin in 2003. In 2006, she obtained a Master degree (MSc) in Epidemiology from the Laval University in Quebec, where she subsequently worked until 2007. From 2008 to 2011, she worked at the National Institute of Public Health of Quebec on several topics including climate change and health impact of uranium mines as research officer. Since 2013, she worked as epidemiologist at the Service of Parasitology and Mycology of University Cheikh Anta Diop of Dakar (UCAD) where she has been involved in several malaria projects. She also attended courses on Good Clinical Practices and on Methodology of Clinical Trials and Practical Implementation.
She plans to pursue a PhD position in Epidemiology and Public Health. Already she has authored/co-authored several articles published in peer reviewed international journals.
A native of Mali, Moussa has been granted a Clinical Research and Development Fellowship from the European and Developing Countries’ Clinical Trials Partnership (EDCTP)/Tropical Diseases Research, World Health Organization (TDR/WHO), which commenced at EVI on 4 January 2018.
Moussa graduated in July 2009 with a Doctorate in Medicine (MD) from the University of Sciences Techniques and Technologies of Bamako/Faculty of Medicine and Dentistry. Subsequently he undertook clinical research at Malaria Research and Training Center (MRTC) as clinical Investigator in the Malaria in Pregnancy Consortium Program (MIPc). In May 2011 he moved to the National Institute of Health (NIH) -Laboratory of Immunogenetics (LIG) program- in collaboration with MRTC, where he was field coordinator for the study “A longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Kalifabougou, Mali”. He has been trained in Good Clinical Practice, introduction of clinical research, clinic research ethics aspects and as site coordinator.
He has been involved in several clinical trials and co-authored several articles published in peer reviewed international journals. In the future, he plans to pursue a master/PhD degree in public health, epidemiology, global health, international health, vaccinology or parasitology-mycology.